ARF5

ARF5 is a small ADP-ribosylation factor GTPase that operates across multiple membrane-trafficking and signaling steps (PMID:22815487, PMID:38679330). At clathrin-coated pits it is activated by the ArfGEF BRAG2/GEP100/IQSec1 to drive clathrin-mediated endocytosis of β1 integrins, a cargo-selective role distinct from bulk transferrin uptake and not substituted by ARF6 (PMID:22815487). It also acts redundantly with ARF1 and ARF4 in ER-to-Golgi export of receptor tyrosine kinases (KIT, PDGFRA, EGFR, MET), a function blocked by the ARF inhibitors BFA/M-COPA (PMID:38679330). In its GTP-bound state ARF5 binds the GORAB golgin through the IGRAB domain to direct GORAB Golgi targeting (PMID:26000619), and it serves as a substrate of the Arf GAP ARAP1 to control actin-ring size at circular dorsal ruffles (PMID:22573888). Beyond trafficking, ARF5 co-localizes with mTOR, Rheb, and PI3,4P2 at plasma membrane ruffles and interacts with the mTORC1 subunit Raptor to recruit mTORC1 and support rapid nutrient-stimulated S6 phosphorylation (PMID:36735494). ARF5 transcription is driven by Sp1/Sp1-like factors binding GC boxes in a TATA-less promoter (PMID:10366714).

1. 1999 Medium

   Established how ARF5 expression is controlled, identifying the cis-elements and trans-factors that drive its transcription.

   Evidence deletion/mutant luciferase reporters, primer extension, and EMSA on the human ARF5 promoter

   PMID:10366714

   Open questions at the time

   • Does not address conditional or signal-responsive regulation of ARF5
   • No link between transcriptional output and ARF5 protein function
2. 2012 High

   Resolved whether ARF5 has a cargo-specific trafficking role, showing it mediates BRAG2-driven clathrin-dependent endocytosis of β1 integrins distinct from other Arfs.

   Evidence siRNA knockdown, rapid-cycling mutant rescue, clathrin/AP-2 co-localization, and cargo-specific internalization assays

   PMID:22815487

   Open questions at the time

   • Mechanism of cargo selectivity over transferrin not defined
   • Downstream effectors at the coated pit not identified
3. 2012 Medium

   Placed ARF5 in an actin-regulatory pathway, identifying it as an ARAP1 GAP substrate controlling dorsal ruffle ring size.

   Evidence ARAP1 overexpression/knockdown with dominant-negative ARF1/ARF5 mutants and CDR size measurement

   PMID:22573888

   Open questions at the time

   • ARF5-specific vs ARF1 contribution not separated
   • Effectors linking ARF5 to actin ring geometry unknown
4. 2015 Medium

   Defined a GTP-dependent ARF5 effector interaction, showing ARF5 binding through the IGRAB domain is required for GORAB Golgi targeting.

   Evidence yeast two-hybrid, trans-Golgi co-localization, BFA treatment, and disease-mutant (GORAB p.Ser175Phe) analysis

   PMID:26000619

   Open questions at the time

   • Functional consequence of GORAB mislocalization for ARF5 trafficking roles not tested
   • Structural basis of IGRAB recognition undetermined
5. 2019 Medium

   Revealed an unexpected RNA-binding capacity, showing ARF5 directly binds viral IRES RNA and modulates IRES-driven translation.

   Evidence proteomic identification, direct RNA-binding assay, RNA-FISH co-localization, and IRES reporter activity

   PMID:30655362

   Open questions at the time

   • Whether RNA binding depends on GTP state untested
   • Physiological relevance beyond viral IRES unknown
6. 2023 High

   Connected ARF5 to nutrient signaling, identifying it as a Raptor partner that recruits mTORC1 to plasma membrane ruffles.

   Evidence Raptor IP/MS, ARF5-GFP co-localization with mTOR/Rheb/PI3,4P2, knockdown, biosensor phosphorylation, and S6 refeeding assays

   PMID:36735494

   Open questions at the time

   • Whether ARF5 GTPase activity is required for mTORC1 recruitment not established
   • Relationship between ruffle trafficking and mTORC1 activation undefined
7. 2023 Low

   Implicated an ARF5–Rab11-FIP4 complex in cancer stem cell properties, linking it to CDK1/cyclin B levels in hepatocellular carcinoma.

   Evidence Co-IP, sphere formation, stemness markers, and CDK1/cyclin B western blot with Rab11-FIP4 knockdown

   PMID:37458957

   Open questions at the time

   • Single Co-IP with no reciprocal validation of ARF5's direct role
   • Phenotype attributed to the complex, not dissected for ARF5 specifically
8. 2024 High

   Defined ARF5's redundant role in early secretion, showing it cooperates with ARF1/ARF4 for ER-to-Golgi export of receptor tyrosine kinases.

   Evidence triple siRNA knockdown, RTK ER-export assay, in vitro BFA/M-COPA pulldown, and apoptosis assays

   PMID:38679330

   Open questions at the time

   • Non-redundant ARF5-specific cargo at this step not identified
   • Order of ARF action in the export pathway unresolved
9. 2024 Medium

   Tested ARF5 requirement in vivo for flavivirus infection, showing complete ARF5 knockout does not alter Zika virus load, unlike ARF4.

   Evidence CRISPR-Cas9 ARF5 knockout mice with RT-qPCR viral load and histopathology

   PMID:39722520

   Open questions at the time

   • Negative result does not exclude redundancy with other Arfs in vivo
   • No assessment of ARF5 loss on its established trafficking cargoes in this model
10. 2025 Low

    Extended the ARF5–Rab11-FIP4 interaction to oocyte endocytic recycling for nanoparticle internalization.

    Evidence Co-IP in oocytes, Rab11fip4 knockdown, endocytic inhibitor treatment, and WGCNA analysis

    PMID:40720586

    Open questions at the time

    • Single Co-IP without reciprocal validation
    • ARF5-specific mechanistic contribution not directly tested

• How ARF5's distinct effector interactions and cargo selectivities are coordinated across endocytosis, secretion, and mTORC1 signaling remains unresolved.
• No structural model distinguishing ARF5 from related Arfs in effector choice
• GEF/GAP regulation integrating its multiple roles not mapped
• Determinants of redundancy vs non-redundancy with ARF1/ARF4 unknown